Frederick Locke, MD
Enriched profileChair, Department of Blood and Marrow Transplant and Cellular Immunotherapy · H. Lee Moffitt Cancer Center and Research Institute
Frederick Locke is Chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy at H. Lee Moffitt Cancer Center and Research Institute. OpenAlex indexes 863 publications with 33,530 citations (h-index 62); ClinicalTrials.gov lists 8 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Hematology / Oncology profiles in the findmyKOL directory.
Data verified 14 Aug 2026
Overview
Updated 27 Aug 2026
Frederick L. Locke, MD, is Chair, Department of Blood and Marrow Transplant and Cellular Immunotherapy at H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL. The public record shows 863 publications with 33,530 citations (h-index 62), centered on Multiple Myeloma, Lymphoma. It also documents an investigator role on 8 registered clinical trials, industry payments reported by 17 companies, 3 NIH-funded awards (2015–2026).
- Most recent indexed publication: 2026 · Bone marrow transplantation
- Top research focus: Multiple Myeloma
- 8 registered trials on ClinicalTrials.gov
- Open Payments reporting from 17 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 43 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Industry payments
Updated 27 Aug 2026
17 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Janssen Scientific Affairs, LLCProgram year20251 payment
- Adaptive Biotechnologies CorporationProgram year20251 payment
- Adaptimmune LLCProgram year20251 payment
NIH funding
Updated 27 Aug 2026
3 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison
H. Lee Moffitt Cancer Ctr & Res Inst
FY2026$1,044,728R01CA244328 - Neurocognitive and Patient-Reported Outcomes after Chimeric Antigen Receptor T-Cell Therapy: A Controlled Comparison
H. Lee Moffitt Cancer Ctr & Res Inst
FY2025$770,748R01CA244328
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma.
Bone marrow transplantation
Article2026 - Axicabtagene Ciloleucel in Combination with Atezolizumab in Patients with Refractory Diffuse Large B-Cell Lymphoma: The Phase 1/2 ZUMA-6 Trial.
Clinical cancer research
Clinical Trial2026
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/frederick-locke-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Frederick-Locke
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - X / Twitter
x.com/DrFredLocke
Mentions by others
where others cite or feature them- Other
treatingbloodcancers.org/e14
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →treatingbloodcancers.org ↗ - Other
moffitt.org/providers/frederick-locke
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
- M.D.
Wayne State University School of Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗ - B.S.
Physiology, Michigan State University
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗ - Board certified
Medical Oncology, American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →health.usnews.com ↗
Editorial & leadership roles
journal and society appointments- Principal investigator
ZUMA-1 and ZUMA-7 clinical trials of axicabtagene ciloleucel (axi-cel) CAR T-cell therapy
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗
Awards & honors
honors on the public record- W. Jackson Pledger Researcher of the Year Award
Moffitt Cancer Center
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →moffitt.org ↗
Secondary affiliations
appointments beyond the home institution- Co-Leader
Immuno-Oncology Program, Moffitt Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →moffitt.org ↗ - Founder/Leader
Immune Cell Therapy (ICE-T) Program, Moffitt Cancer Center
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →expertperspectives.com ↗
Media & interviews
press, podcasts and appearances- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
- Medscape InDiscussion podcast series
"Episode 6: The Future of CAR T-cell Therapy"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medscape.com ↗ - CancerNetwork video interview with Michael Jain
MD, PhD: "Why Some Patients With Lymphoma Do Not Respond to Cellular Immunotherapy"
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →cancernetwork.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.